Gilead Sciences has signed royalty-free licensing deals with three generic drugmakers that would make its experimental Ebola prevention drug, obeldesivir, available across 127 mainly low- and lower-middle-income countries — but only if the drug succeeds in trials and wins regulatory approvals.
The agreements were announced on Monday.
The deals cover Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories, and include all African countries reporting cases in the current Ebola Bundibugyo outbreak. The drug itself remains unproven: obeldesivir has shown activity against several Ebola-related viruses in preclinical studies, and it is not approved for any use in any country.
Why sign manufacturing deals for a drug that may never be approved? The answer, per the company’s own framing, is to line up manufacturing and supply before trial results and regulatory filings. A late-stage trial is currently testing obeldesivir in people at high risk after exposure, and the agreements are intended to line up manufacturing and supply chains before trial results and regulatory filings arrive.
Gilead is also expanding remdesivir licenses to cover Ebola-related diseases, again conditional on positive trial results and regulators approving the drug. The company has given away upwards of 38,000 vials of remdesivir to the Democratic Republic of Congo, Uganda and Kenya, among them over 2,000 doses shipped recently to Kenya for investigational treatment and post-exposure prevention.

No approved Ebola drug exists yet
- No Ebola drug here is approved yet. Obeldesivir is experimental, and remdesivir has no regulatory approval for treating or preventing Ebola Bundibugyo disease — how well it works in patients remains unproven.
- The point of the deals is readiness, not treatment. By securing generic manufacturing now, Gilead aims to line up manufacturing and supply before trial results and regulatory filings.
- Everything hinges on trial results. A late-stage trial is testing the drug in people at high risk after exposure.
How the drugs work, and what remains unproven
What distinguishes the two drugs is their regulatory status. Remdesivir carries no approval for treating or preventing Ebola Bundibugyo disease, and how effective it is clinically has yet to be demonstrated. Obeldesivir has demonstrated activity against multiple Ebola-related viruses in preclinical studies but holds no approval for any use in any country.
The late-stage trial now underway targets people at high risk after exposure.
Why the licensing structure matters
Royalty-free licensing means the generic manufacturers — Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories — can produce and supply the drug. Coverage spans 127 mainly low- and lower-middle-income countries, including all African countries reporting cases in the current Ebola Bundibugyo outbreak.
Gilead grants voluntary licenses of experimental Ebola drug to Dr Reddy’s, two others#Ebola I #antiviral I #Voluntary_License I #AfricaOutbreak I @GileadSciences I @drreddys Read more:https://t.co/tLIeGW0Ttr
Pre-negotiating supply before the data arrive is an attempt to line up manufacturing and supply.
| Element | Obeldesivir | Remdesivir |
|---|---|---|
| Status | Experimental; not approved for any use in any country | Not approved to treat or prevent Ebola Bundibugyo disease |
| Ebola evidence so far | Activity against several Ebola-related viruses in preclinical studies | Clinical effectiveness has not been established |
| Current role | Late-stage trial testing the drug in people at high risk after exposure | Donated more than 38,000 vials to the Democratic Republic of Congo, Uganda and Kenya |
| Licensing | Royalty-free deals, 127 countries | Expanding licenses to cover Ebola-related diseases, conditional on results |
The funding and bias picture
The donation of remdesivir vials to the Democratic Republic of Congo, Uganda and Kenya is investigational. Remdesivir lacks approval for the treatment or prevention of Ebola Bundibugyo disease, and there is no established evidence of its clinical effectiveness.
Remdesivir not approved for Ebola Bundibugyo
There is no approval for remdesivir as a treatment for or prevention of Ebola Bundibugyo disease, and its effectiveness in clinical settings remains unestablished.
A late-stage trial is testing the drug in people at high risk after exposure. The deals are intended to line up manufacturing and supply before trial results and regulatory filings.
References
- Gilead Sciences, November 18, 2026
- Reuters, November 16, 2026
Disclaimer: This article is journalistic reporting and does not constitute medical advice.